宋世琪,李 妍

近年来关于FN1在卵巢癌中的研究逐渐增多，大量证据表明卵巢癌组织中FN1的表达水平显著高于正常卵巢组织。FN1的过表达与卵巢癌的恶性程度、肿瘤细胞的迁移和侵袭能力以及患者的预后密切相关。研究发现，FN1通过其与细胞外基质的相互作用，促进卵巢癌细胞的转移，特别是在腹腔转移过程中，FN1的作用尤为突出。此外，FN1的表达还与卵巢癌的耐药性相关，通过增强细胞的生存信号途径，减少对化疗药物的敏感性。FN1有望成为卵巢癌的新型预后标志物，且成为未来卵巢癌治疗的潜在靶点。本文结合 FN1表达水平与卵巢癌预后的相关性进行分析，以供参考。

FN1表达水平；卵巢癌预后；相关性

[1] 周琛博,武劼.SRGAP1 PLOD2 CtBP2在卵巢癌中的表达及与预后的相关性[J].中国妇幼保健,2025,40(06):1102-1106. [2] 杨至纯,朱晓华.卵巢癌组织KLF5的表达及与患者临床病理特征､预后的相关性[J].现代实用医学,2025,37(02):129-133. [3] Millapán T,GutiérrezÁ,Rosas K,et al.In Silico Insights Reveal Fibronectin 1 as a Theranostic Marker in Gastric Cancer[J].International Journal of Molecular Sciences,2024,25(20):11113-11113. [4] Ishihara Y,Miyamoto Y,Esumi S,et al.Structural diversity inside the mouse subiculum revealed by a new marker protein fibronectin 1[J]. Anatomical Science International,2024,100(2):1-21. [5] Shen A,Dai L,Zhou D,et al.Fibronectin 1 serves as a potential diagnostic,immunological and prognostic biomarker for glioblastoma patients.[J].Asian journal of surgery,2024,48(3):2091-2092. [6] 何倩,何爱琴.术前血清CA125､凝血酶原时间对上皮性卵巢癌预后及铂耐药的预测价值[J].吉林医学,2024,45(12):2913-2917. [7] 雷雨晨,李婷,王日昕,等.不饱和脂肪酸相关酶CBR1､ALOX15和FADS1在上皮性卵巢癌组织中的表达与预后相关性分析[J].肿瘤代谢与营养电子杂志,2024,11(06):797-804. [8] 岳红,汤进,陈钢.血清ALP､HE4联合SII指数与卵巢癌肿瘤良恶性程度相关性及预后影响因素分析[J].临床和实验医学杂志, 2024,23(22):2412-2416. [9] 刘军,丁长春,樊祖康.CT增强图像纹理分析技术在卵巢癌术前定量恶性程度及新辅助化疗预后评估中的价值[J].中国妇幼保健, 2024,39(22):4574-4577. [10] Bhattarai P,Gunasekaran I T,Dumeyer R D,et al.Rare genetic variation in Fibronectin 1(FN1)protects against APOEe4 in Alzheimer's disease.[J].bioRxiv:the preprint server for biology,2024, [11] Rania A,H R M,Abdlrehim A B,et al.Vincamine Ameliorates Epithelial-Mesenchymal Transition in Bleomycin-Induced Pulmonary Fibrosis in Rats;Targeting TGF-β/MAPK/Snai1 Pathway.[J].Molecules(Basel,Switzerland),2023,28(12): [12] Guochao Y,Xiaomei Z,Mansheng L,et al.Integrated analysis of circulating and tissue proteomes reveals that fibronectin 1 is a potential biomarker in papillary thyroid cancer[J].BMC Cancer,2023,23(1):412-412. [13] C B A O,Oyumergen A,Pengfei C,et al.The long noncoding RNA PRANCR is associated with alternative splicing of fibronectin-1 in keratinocytes.[J].The Journal of investigative dermatology,2023,143(9):1825-1830.e6. [14] Shifang S,Yifan Z,Ningjie X,et al.Long non-coding RNA ATB expedites non-small cell lung cancer progression by the miR-200b/ fibronectin 1 axis.[J].Journal of clinical laboratory analysis,2023,37(4):e24822-e24822. [15] L J L,Natalia H,Mercedes R D,et al.PRPF8 increases the aggressiveness of hepatocellular carcinoma by regulating FAK/AKT pathway via fibronectin 1 splicing.[J].Experimental&molecular medicine,2023,55(1):132-142. [16] Siwei P,Jiaming Z,Pengfei L,et al.FN1 mRNA 3'-UTR supersedes traditional fibronectin 1 in facilitating the invasion and metastasis of gastric cancer through the FN1 3'-UTR-let-7i-5p-THBS1 axis.[J].Theranostics,2023,13(14):5130-5150. [17] Liang Z,Yan W,Minghan S,et al.Fibronectin 1 as a Key Gene in the Genesis and Progression of Cadmium-Related Bladder Cancer.[J]. Biological trace element research,2022,201(9):4349-4359. [18] 王娟,刘蕾蕾,李琰,等.CDH1单核苷酸多态性与上皮性卵巢癌患者临床预后的关联性[J].河北医药,2024,46(11):1611-1616. [19] Song W,Chang L,Xing W,et al.High Expression of Fibronectin 1 Predicts a Poor Prognosis in Glioblastoma.[J].Current medical science,2022,42(5):1055-1065. [20] Murad A,Wei Y,Rongxiang H,et al.Corrigendum to“Insights into the implementation of Fibronectin 1 in the cartilage tissue engineering”[Biomed.Pharmacother.148(2022)112782][J].Biomedicine&Pharmacotherapy,2022,153 113539-113539. [21] 李苗,龚姗,金海红,等.上皮性卵巢癌组织CDCA7表达水平及其与患者预后的相关性研究[J].现代检验医学杂志, 2023,38(02):118-123. [22] 隋磊,纪晓宇,朱晓瑛,等.卵巢癌组织中lncRNA NORAD的表达水平及其与临床病理特征和预后的相关性[J].现代肿瘤医学, 2023,31(01):152-155. [23] 李品,刘春晖,石军荣,等.卵巢癌患者血清微小RNA 128的表达水平及与化疗效果和预后的相关性研究[J].现代检验医学杂志, 2022,37(06):104-109. [24] 邰莹,吕小慧,任彦洁,等.外周血sCTLA-4､sPD-L1及Ki-67在晚期卵巢癌中表达水平及与预后的相关性分析[J].临床和实验医学杂志,2022,21(21):2307-2311. [25] 邓森灵,兰代群,曹雅文,等.上皮性卵巢癌患者血清miR-362和miR-485的表达水平及其与预后的相关性研究[J].现代检验医学杂志,2022,37(04):35-37+42. [26] 唐坤,霍炽文,欧阳志维.人附睾蛋白4在卵巢肿瘤患者中的表达水平与卵巢癌预后生存期的相关性研究[J].黑龙江医药, 2022,35(03):677-679. [27] 王晓辉,奈嫚嫚,李蕾,等.HK2､CXCR4基因表达水平与卵巢癌临床病理及生存预后的相关性[J].热带医学杂志, 2020,20(06):741-745. [28] 马欢,田小飞,李红霞.复发性卵巢癌患者血清NDRG4水平表达与临床特征及预后的相关性研究[J].现代检验医学杂志, 2019,34(05):81-83. [29] 赵春梅.外周血调节性T细胞表达水平与卵巢上皮癌预后的相关性[J].实用临床医药杂志,2014,18(11):182-184.

点击下载PDF